Zions Bancorporation N.A. Reduces Holdings in Johnson & Johnson (NYSE:JNJ)

Zions Bancorporation N.A. trimmed its holdings in shares of Johnson & Johnson (NYSE:JNJFree Report) by 18.8% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 4,414 shares of the company’s stock after selling 1,022 shares during the period. Zions Bancorporation N.A.’s holdings in Johnson & Johnson were worth $687,000 at the end of the most recent reporting period.

Other institutional investors have also made changes to their positions in the company. Hibernia Wealth Partners LLC bought a new stake in shares of Johnson & Johnson in the third quarter worth $27,000. FNY Investment Advisers LLC bought a new stake in shares of Johnson & Johnson in the third quarter worth $37,000. Tower View Wealth Management LLC increased its stake in shares of Johnson & Johnson by 183.3% in the third quarter. Tower View Wealth Management LLC now owns 255 shares of the company’s stock worth $40,000 after buying an additional 165 shares during the last quarter. Creative Capital Management Investments LLC increased its stake in shares of Johnson & Johnson by 43.0% in the third quarter. Creative Capital Management Investments LLC now owns 286 shares of the company’s stock worth $45,000 after buying an additional 86 shares during the last quarter. Finally, VitalStone Financial LLC bought a new stake in shares of Johnson & Johnson in the second quarter worth $48,000. 68.40% of the stock is owned by institutional investors and hedge funds.

Johnson & Johnson Stock Performance

JNJ stock opened at $157.98 on Thursday. The company has a market capitalization of $380.30 billion, a P/E ratio of 11.44, a PEG ratio of 2.62 and a beta of 0.53. The company has a 50-day simple moving average of $158.20 and a 200 day simple moving average of $159.04. Johnson & Johnson has a fifty-two week low of $144.95 and a fifty-two week high of $175.97. The company has a quick ratio of 0.96, a current ratio of 1.21 and a debt-to-equity ratio of 0.37.

Johnson & Johnson (NYSE:JNJGet Free Report) last posted its quarterly earnings data on Tuesday, January 23rd. The company reported $2.29 earnings per share for the quarter, topping the consensus estimate of $2.28 by $0.01. The business had revenue of $21.40 billion during the quarter, compared to the consensus estimate of $21.02 billion. Johnson & Johnson had a net margin of 37.79% and a return on equity of 36.75%. The company’s quarterly revenue was down 9.7% compared to the same quarter last year. During the same quarter in the prior year, the company posted $2.35 earnings per share. Sell-side analysts predict that Johnson & Johnson will post 10.66 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 5th. Shareholders of record on Tuesday, February 20th will be issued a $1.19 dividend. This represents a $4.76 dividend on an annualized basis and a yield of 3.01%. The ex-dividend date of this dividend is Friday, February 16th. Johnson & Johnson’s payout ratio is 34.47%.

Analyst Ratings Changes

A number of brokerages recently issued reports on JNJ. Royal Bank of Canada restated an “outperform” rating and issued a $181.00 price target on shares of Johnson & Johnson in a research note on Wednesday, January 24th. Wells Fargo & Company lowered shares of Johnson & Johnson from an “overweight” rating to an “equal weight” rating and lowered their target price for the company from $170.00 to $163.00 in a research note on Wednesday, December 13th. StockNews.com upgraded shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Tuesday. UBS Group upgraded shares of Johnson & Johnson from a “neutral” rating to a “buy” rating and boosted their target price for the company from $167.00 to $180.00 in a research note on Friday, December 1st. Finally, Raymond James boosted their target price on shares of Johnson & Johnson from $172.00 to $175.00 and gave the company an “outperform” rating in a research note on Wednesday, January 3rd. Eight analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Johnson & Johnson has an average rating of “Moderate Buy” and a consensus price target of $176.14.

View Our Latest Stock Report on Johnson & Johnson

Johnson & Johnson Company Profile

(Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.

Further Reading

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJFree Report).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.